We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adimab and Mersana Announce Antibody-Drug Conjugate Alliance
News

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance
News

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adimab and Mersana Announce Antibody-Drug Conjugate Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adimab, LLC and Mersana Therapeutics, Inc. have announced the initiation of a joint effort to offer integrated antibody discovery and ADC technologies.

The alliance is built to offer pharmaceutical companies seamless access to Adimab’s world-class antibodies that have been specifically optimized for use in ADCs together with Mersana’s Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads.

“We are excited to couple Mersana’s innovative ADC technology with our platform for use by the pharmaceutical industry. The flexibility in payloads, linkers and drug loading enabled by Mersana’s Fleximer technology complements Adimab’s philosophy of tailoring drug development to the biology of the target of interest,” said Adimab CEO Tillman Gerngross.

Gerngross continued, “With this deal, Adimab is further expanding its footprint beyond monoclonal antibody discovery. We view ADCs, as well as other aspects of antibody discovery such as bispecific formats, as important tools in the development of novel therapeutics.”

“Over the past three years Adimab has established itself as the premier therapeutic antibody discovery company in the industry,” said Mersana CEO Nicholas Bacopoulos.

Bacopoulos continued, "We are excited to combine Adimab’s technology with our highly differentiated ADC platform consisting of our clinically validated Fleximer polymer, diverse linkers and a wide variety of payloads. Adimab’s tailored approach fits perfectly with the customized design of Fleximer ADCs and together we can provide ADCs with increased likelihood of target selectivity and therapeutic efficacy. With our recently announced financing, this alliance represents a significant step forward in the company's transformation into a next-generation ADC company.”

Advertisement